Asparagine Specific Enzymes (Erwinaze, Rylaze, Oncaspar, Asparlas)
Customize your policy alerts
Sign up for Anthem Policy CC-0096 alerts
Get alerted when Policy CC-0096 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage criteria and coding for asparagine-specific enzyme therapies (Erwinaze, Rylaze, Oncaspar, Asparlas) primarily for acute lymphoblastic leukemia (ALL) and select lymphomas; governs prior authorization/medical necessity determinations for Anthem members.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.